Vimarsana
Biggest News Aggregation in the World

Page 41 - Opposition Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Opposition Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Opposition Division Today - Breaking & Trending Today

Beyond "pay-for-delay" – the EU-Commission's investigation into patent filing practices and communication measures | Allen & Overy LLP - Vimarsana News

Beyond "pay-for-delay" – the EU-Commission's investigation into patent filing practices and communication measures | Allen & Overy LLP

[co-authors: On 4 March 2021, the European Commission ( Commission) opened a formal investigation into alleged anti-competitive conduct by the pharmaceutical company Teva. The Commission suspects Teva of having deployed a strategy with the intention of delaying the market entry of generic drugs that competed with Teva’s originator drug Copaxone. This may have amounted to an abuse of a dominant position prohibited under Art. 102 TFEU, the Commission states in its press release. While the Commission has sanctioned patent settlements that delay the market entry of generic drugs (“pay-for-de...

This week in IP: Germany wipes up litigation, SCOTUS hears Minerva, Chanel loses Huawei TM battle - Vimarsana News

This week in IP: Germany wipes up litigation, SCOTUS hears Minerva, Chanel loses Huawei TM battle

Germany cleans up in European patent litigation According to statistics on European litigation exclusively revealed by Managing IP this week, German courts have been wiping up European patent litigation since 2015. The data, provided by Darts-IP, shows that Germany took in 3,692 cases between 2015 and 2019, compared to 673 in Italy, 503 in France, 492 in the Netherlands and 430 in the UK, the next four most popular countries for European patent litigation. German courts also featured the most frequently in the list of the top 10 most popular European courts for patent cases, with the Düssel...

Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020 - Vimarsana News

Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020

Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020 Forward Pharma A/S Hawthorne, New York, UNITED STATES COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the ye...

CJEU gives mixed ruling in Puma TM infringement case - Vimarsana News

CJEU gives mixed ruling in Puma TM infringement case

The Court of Justice of the European Union has dismissed the majority of a complaint from sportswear brand Puma regarding a trademark application by German milling technology company CAMäleon.

Review Of EPO Parameter Decisions In 2020 - Intellectual Property - Vimarsana News

Review Of EPO Parameter Decisions In 2020 - Intellectual Property

To print this article, all you need is to be registered or login on Mondaq.com. Before the EPO parameters are defined as features which are based on directly measurable properties or combinations of several variables in the form of formulae. This might be a claim defined by the viscosity of a composition, or the particle size of a powder, for example. Relying on such features to define an invention is commonplace within the chemical sphere and can be very useful. However, their utility is not limited to such subject matter and they could be used to define characteristi...

Source: mondaq.com